Neurocrine Biosciences has shared survey data showing how tardive dyskinesia affects the ability of patients and caregivers to work, supporting the company’s case for timely treatment of the movement disorder.
Biotech’s new company model; The super poop behind a startup launch; and more
Welcome back to another edition of Endpoints Weekly! Earnings season is in full swing, but we had plenty of original reporting and exclusives you won’t


